查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2034903

全球生物醫學瓣膜市場：市場規模、佔有率和趨勢分析（2026-2032 年）

Tissue Heart Valve Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Stented, Stentless, and 1 Other Tissue Heart Valve
出版日期: | 出版商: iData Research Inc. | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球生物醫學瓣膜市場報告（至2032年）

2025年全球生物瓣膜市場規模為18億美元。預計到2032年，該市場將以1.1%的複合年成長率成長，達到19億美元。

本報告涵蓋了全球生物瓣膜市場，包括用於外科瓣膜置換術的帶支架、無支架和無縫線生物瓣膜。

分析內容包括銷售量、平均售價 (ASP)、手術數量、市場規模、市場佔有率、成長趨勢、到 2032 年的市場預測以及到 2022 年的歷史數據。

市場成長主要受以下因素驅動：消費者對生物瓣膜的持續青睞、生物瓣膜耐久性的提升以及無支架和無縫線技術的應用。然而，機械瓣膜的改良和經導管主動脈瓣置換術（TAVI）的普及預計將抑制市場更強勁的成長。

市場概覽

全球生物瓣膜市場涵蓋用於替換病灶或受損心臟瓣膜的生物瓣膜。這些產品通常用於需要瓣膜置換術或希望避免終身抗凝血治療的患者。

該市場涵蓋帶支架、無支架和無縫線生物瓣膜。帶支架生物瓣膜因其成熟的臨床應用和外科醫生的熟悉程度而仍被廣泛使用。同時，無支架和無縫線生物瓣膜因其有望改善血流動力學性能和縮短手術時間而備受關注。

生物瓣膜通常優於機械瓣膜，因為它們能更真實地模擬天然瓣膜的功能，並具有更高的生物相容性。這使得它們成為許多患者，尤其是老年患者的理想選擇。

無縫線和無支架生物瓣膜的日益普及正在推動市場成長。這些技術透過改善血流動力學性能和降低手術複雜性，有助於克服傳統支架瓣膜的一些限制。它們的應用正在積極促進生物瓣膜的整體使用率。

市場促進因素

生物瓣膜的偏好

生物瓣膜市場的主要驅動力是人們對生物瓣膜而非機械瓣膜的持續偏好。生物瓣膜具有更好的生物相容性，並且能更真實地模擬天然心臟瓣膜的功能。

機械瓣膜可能引起免疫反應問題，並增加血栓形成的風險。因此，接受機械瓣膜植入的患者需要終身接受抗凝血治療。

接受組織瓣膜植入的患者通常無需終身抗凝血治療。考慮到長期安全性、對日常生活的影響以及監測需求之間的平衡，這對於外科醫生和患者而言都是一項顯著優勢。因此，組織瓣膜的市佔率持續從機械瓣膜手中奪取。

提高耐用性

機械閥比生物閥更耐用，但由於製造方法和產品技術的進步，生物閥的耐用性也隨著時間的推移而提高。

目前，生物瓣膜的平均使用壽命通常為10至15年。此外，許多瓣膜的功能持續時間可長達20年，具體取決於患者和產品本身。

由於生物瓣膜的主要目標患者群體是65歲及以上的老年人，因此植入的瓣膜通常需要10到15年的使用壽命才能在患者餘生中發揮作用。隨著耐久性的進一步提高，生物瓣膜也可能成為年輕患者的合適選擇，從而有可能擴大其適用族群。

無支架生物瓣膜

在某些情況下，無支架組織瓣膜通常優於有支架組織瓣膜瓣膜。有支架瓣膜中使用的支架連接結構會限制血液流經瓣膜，尤其是在需要較小瓣膜的患者身上。

無支架瓣膜的主要優點在於其更大的瓣膜開口，使血液更自由、更自然地流動。這改善了血液動力學，並減少了瓣膜和周圍心肌組織的機械應力。

減輕應力也有助於提高瓣膜的耐久性。採用特殊的組織處理方法可以增強無支架瓣膜的耐久性，長期數據顯示，這些產品的平均使用壽命比有支架瓣膜更長。

市場限制

機械閥的改進

機械瓣膜技術的進步預計將抑制生物瓣膜市場的擴張。機械瓣膜本身俱有很高的耐用性，這仍然是其相對於生物瓣膜的主要優勢。

機械瓣膜製造材料可望持續改進。理想情況下，這些改進將減少血栓形成，並降低抗凝血治療的需求，並使機械瓣膜的使用更加頻繁。

如果機械瓣膜的安全性提高，抗凝血治療的管理負擔減輕，它們可能會重新獲得患者和外科醫生的支持。如果這種情況發生，組織瓣膜從機械瓣膜產品中奪取市場佔有率的速度將會放緩。

經導管主動脈瓣置換術

經導管主動脈瓣置換術術（TAVI）是傳統外科組織瓣膜應用的一大阻礙因素。儘管開胸手術仍然是治療主動脈瓣狹窄的常用方法，但TAVI技術正在迅速擴大市場佔有率。

目前，經導管主動脈瓣置換術（TAVI）核准用於合格手術、高風險和中度風險的患者。隨著TAVI手術的普及，接受外科組織組織瓣膜置換術的患者數量將會減少。

經導管主動脈瓣置換術（TAVI）的核准及其在低風險患者群體中的應用範圍擴大，將進一步蠶食外科手術中使用的傳統生物瓣膜的市場佔有率。預計在整個預測期內，這仍將是市場面臨的最主要壓力之一。

市場成長溫和

全球生物瓣膜市場預計到 2032 年將以 1.1% 的適度複合年成長率成長。雖然生物瓣膜在臨床上仍然非常重要，但該市場已經成熟，並面臨競爭治療方法的壓力。

耐用性的提升、患者的偏好以及瓣膜的特殊設計正在推動市場成長。然而，經導管治療的興起以及其他競爭技術的不斷進步正在抵消這些積極因素的影響。

因此，供應商需要專注於產品改進、外科醫生信任、耐用性數據和全球市場准入，以在低成長市場中保持穩定的績效。

市場覆蓋範圍和數據範圍

  • 定量分析：市場規模、市場佔有率、手術數量、市場預測、市場成長率、銷售單位數、平均售價。
  • 定性範圍：市場促進因素和阻礙因素、競爭分析、近期併購、公司簡介、產品系列和主要競爭對手。
  • 目標時期：基準年為 2025 年，預測至 2032 年，歷史資料截至 2022 年。
  • 建立市場模型：收入分析採用銷售量和平均售價（ASP），並輔以手術數量、競爭市場佔有率分析和預測假設。
  • 目標器械：本報告涵蓋用於外科心臟瓣膜置換術的生物瓣膜，包括帶支架、無支架和無縫線生物瓣膜。

目標市場及區隔

生物醫學閥門市場

  • 器械類型：有支架、無支架和無縫線心臟瓣膜。

支架支撐式生物瓣膜是一種廣泛應用的、由支架支撐的外科生物瓣膜。由於其悠久的臨床應用歷史、外科醫生的高度熟悉度以及在全球市場的廣泛普及，這類產品仍佔據著重要的地位。

無支架生物瓣膜的設計無需支撐支架結構。這使得瓣膜開口可以更大，從而支持更自然的血液流動，尤其適用於需要較小瓣膜的患者。

無縫線組織心臟瓣膜旨在縮短植入時間並簡化手術流程。這些產品有助於縮短手術時間，並可能促進其在對手術效率要求極高的病例中的應用。

每個細分市場都根據市場規模、市場佔有率、治療次數、市場預測、市場成長率、銷售量和平均售價進行分析。

這種市場細分使製造商、投資者和策略團隊能夠了解瓣膜類型、耐用性、外科醫生偏好、患者選擇和相互競爭的經導管治療方案如何塑造全球生物瓣膜市場。

競爭分析

截至2025年，愛德華生命科學公司是生物人工心臟瓣膜市場的全球領導者。該公司提供Carpentier-Edwards®系列外科心臟瓣膜，其主動脈生物人工瓣膜產品則透過PERIMOUNT®產品組合提供。

愛德華生命科學公司充分發揮自身優勢：強大的全球影響力、成熟的產品線以及長期以來贏得醫生的信賴。預計這些因素將使該公司在整個預測期內保持其市場佔有率。

美敦力是全球生物瓣膜市場第二大競爭對手。其產品系列包括Hancock™、Mosaic™、Avalas™及其他外科瓣膜產品系列。 Hancock™和Mosaic™支架式生物瓣膜可用於主動脈瓣和二尖瓣置換術。

美敦力公司於2024年4月在美國推出了其新一代外科主動脈組織瓣膜Avalus Ultra™。隨後，該產品於2024年10月在西歐進行商業部署，並於2025年10月在印度上市。這種分階段擴張的策略反映了美敦力公司擴大先進組織瓣膜技術應用範圍的策略。

截至2025年，雅培是全球第三大競爭對手。該公司目前主要由Epic™二尖瓣和主動脈支架式組織瓣膜組織瓣膜，此前，由於有報告指出Trifecta™瓣膜存在結構性瓣膜過早劣化的情況，該公司於2023年停止生產Trifecta™瓣膜。這削弱了雅培的地位，尤其是在北美地區，而且在來自愛德華生命科學、美敦力和科西姆等公司的激烈競爭下，預計雅培難以獲得顯著的市場佔有率。

技術和臨床趨勢

採用無增壓器氣門

無縫線生物瓣膜因其能夠縮短手術時間並簡化植入過程而備受關注。這在心臟外科手術中至關重要，因為手術時間的縮短有助於提高手術效率並減少麻醉時間。

預計這些設備在未來仍將是產品開發的重要領域。

無支架瓣膜的性能

無支架生物瓣膜可以透過擴大瓣膜開口和實現更自然的血液流動來改善血液動力學性能。

這種設計對於需要較小瓣膜的患者來說尤其有用，因為帶有支架的設計可能會限制血流。

組織處理技術的改進

組織處理技術的進步提高了瓣膜的耐用性。隨著瓣膜預期使用壽命的延長，其耐用性的提高使得組織瓣膜對患者和醫生都更具吸引力。

隨著耐用性的提高，未來可能會考慮將生物瓣膜用於更年輕的患者群體。

減少抗凝血治療的需求

生物瓣膜最大的優點之一在於無需終身服用抗凝血藥物。這項優勢鼓勵患者自主選擇，並有助於將生物瓣膜與機械瓣膜區分開來。

減輕老年患者的長期用藥負擔尤其重要。

經導管主動脈瓣膜置換術（TAVI）引發了外科瓣膜市場的競爭。

經導管主動脈瓣置換術（TAVI）持續革新瓣膜置換術領域。隨著經導管技術的應用範圍不斷擴大，傳統外科生物瓣膜正面臨激烈的競爭壓力。

這種趨勢在主動脈瓣置換術中尤其明顯。

全球產品擴張

主要企業正在關鍵地區擴大生物瓣膜的供應。美敦力公司Avalus Ultra™在美國、西歐和印度的逐步上市，反映了擴大新型外科瓣膜技術應用範圍的更廣泛趨勢。

全球範圍內的外科醫生分銷和招募工作仍將是重要的競爭因素。

地區

本報告涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

這份報告的意義

  • 全球生物瓣膜市場目前的規模有多大？預計到 2032 年將成長多少？
  • 隨著時間的推移，銷售量、治療量、平均售價（ASP）和市場規模發生了什麼樣的變化？
  • 哪種類型的組織瓣膜是市場需求的主要促進因素？
  • 有支架、無支架和無縫線組織瓣膜在應用和成長率方面有何異同？
  • 為什麼外科醫生和病人通常更喜歡組織瓣膜而不是機械瓣膜？
  • 提高耐久性如何擴大組織瓣膜的潛在病患群體？
  • 無支架瓣膜在改善血流和長期療效方面發揮什麼作用？
  • 經導管主動脈瓣置換術（TAVI）對傳統外科生物瓣膜置換術的需求有何影響？
  • 哪些公司是全球生物瓣膜市場的主要企業？
  • Edwards Lifesciences、Medtronic 和 Abbott 在競爭格局中處於什麼位置？

iData Research 的《全球生物醫學瓣膜市場報告》透過設備層級分析、基於手術流程的建模、平均售價 (ASP) 數據、企業市場占有率分析以及到 2032 年的預測來解答這些問題。利用這份報告來評估需求、與競爭對手進行比較、了解外科瓣膜趨勢，並協助制定全球生物醫學瓣膜市場的產業計畫。

目錄

調查方法

  • 第一步：專案啟動與團隊組建
  • 步驟 2：準備資料系統並進行二次調查。
  • 步驟 3：設計和準備訪談和調查問卷。
  • 第四步：進行初步調查
  • 第五步：調查與分析：建立基準估計值
  • 第六步：市場預測與分析
  • 步驟 7：辨識策略機遇
  • 步驟 8：最終審核和市場推廣
  • 步驟九：客戶回饋與市場監測

全球關稅的影響

組織心臟瓣膜市場

  • 執行摘要
    • 全球組織心臟瓣膜市場概覽
    • 競爭分析
    • 目標程式
    • 目標市場
    • 目標區域
  • 介紹
  • 手術次數
    • 全組織心臟瓣膜手術
    • 主動脈組織心臟瓣膜手術
    • 二尖瓣組織心臟瓣膜手術
    • 三尖瓣手術
    • 肺組織心臟瓣膜手術
  • 市場概覽
    • 按細分市場
    • 按地區
  • 市場分析與預測
    • 整體組織心臟瓣膜市場
    • 帶支架的組織心臟瓣膜市場
    • 無支架組織心臟瓣膜市場
    • 無縫線組織心臟瓣膜市場
  • 促進因素和抑制因素
  • 競爭性市佔率分析

附錄

Product Code: iDATA_GLCS26_THV_MC

Global Tissue Heart Valve Market Report to 2032

The global tissue heart valve market was valued at $1.8 billion in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 1.1%, reaching $1.9 billion by 2032.

This report covers the global market for tissue heart valves, including stented, stentless, and sutureless tissue heart valves used in surgical valve replacement procedures.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by continued preference for tissue valves, improved tissue valve durability, and adoption of stentless and sutureless technologies. However, improvements in mechanical valves and the expansion of transcatheter aortic valve implantation are expected to limit stronger growth.

Market Overview

The global tissue heart valve market includes bioprosthetic valves used to replace diseased or damaged heart valves. These products are commonly used in patients who require valve replacement but prefer to avoid lifelong anticoagulation therapy.

The market includes stented, stentless, and sutureless tissue heart valves. Stented tissue valves remain widely used because of their established clinical history and familiarity among surgeons. Stentless and sutureless options are gaining attention because they may improve blood flow performance and reduce operative time.

Tissue heart valves are often preferred over mechanical valves because they more closely mimic natural valve function and are more biocompatible. This makes them an attractive option for many patients, especially older adults.

Increased adoption of sutureless and stentless tissue valves is supporting market growth. These technologies help address some limitations of traditional stented valves by improving hemodynamic performance and reducing procedural complexity. Their use is contributing positively to overall tissue valve utilization.

Market Drivers

Preference for Tissue Valves

The main driver of the tissue heart valve market is the continued preference for tissue valves over mechanical options. Tissue valves are more biocompatible and mimic the natural heart valve more closely than mechanical valves.

Mechanical valves can trigger immune response issues and increase the risk of blood clot formation. Because of this, patients who receive mechanical valves require lifelong anticoagulation therapy.

Patients who receive tissue valves generally do not require lifelong anticoagulation therapy. This is an important benefit for both surgeons and patients, especially when balancing long-term safety, lifestyle impact, and monitoring requirements. As a result, tissue valves have continued to cannibalize the mechanical valve market.

Improved Durability

Mechanical valves are more durable than tissue valves, but tissue valve durability has improved over time due to better processing methods and product technology.

Tissue valves now typically last 10 to 15 years on average. Many valves have also been shown to remain functional for 20 years, depending on the patient and product.

Because the largest patient demographic for tissue valves is the 65 and older age group, a 10 to 15-year lifespan is often sufficient for the implanted valve to last for the remainder of the patient's life. As durability continues to improve, tissue valves may become suitable for progressively younger patients, expanding the eligible treatment population.

Stentless Tissue Valves

Stentless tissue valves are often preferred over stented tissue valves in certain cases. The stent mounting used in stented valves can limit blood flow through the valve, particularly for patients who need smaller valve sizes.

The main advantage of a stentless valve is its wider valve opening, which allows blood to flow more freely and more naturally. This can improve hemodynamic performance and reduce mechanical stress on the valve and surrounding heart tissue.

Reduced stress may also support longer valve durability. Special tissue treatments are intended to make stentless valves more durable, and long-term data may show that these products last longer than stented valves on average.

Market Limiters

Improvements in Mechanical Valves

Improvements in mechanical heart valve technology are expected to limit the tissue heart valve market. Mechanical valves already offer high levels of durability, which remains their main advantage over tissue valves.

Materials used in mechanical valve production are expected to continue improving. Ideally, these improvements will reduce clot formation and allow mechanical valves to be used more often with less need for anticoagulation therapy.

If mechanical valves become safer and require less intensive anticoagulant management, they could regain appeal among patients and surgeons. This would limit the rate at which tissue valves continue to take share from mechanical valve products.

Transcatheter Aortic Valve Implantation

Transcatheter aortic valve implantation is a major limiter for traditional surgical tissue heart valves. Open surgery remains a common approach for treating aortic stenosis, but TAVI procedures are rapidly taking market share.

TAVI devices are currently approved for inoperable, high-risk, and intermediate-risk patients. As these procedures become more widely adopted, they reduce the number of patients treated with surgical tissue heart valve replacement.

The approval and expansion of TAVI into lower-risk patient groups will have a further cannibalizing effect on traditional tissue valves used in surgery. This is expected to remain one of the most important pressures on the market over the forecast period.

Slow Market Growth

The global tissue heart valve market is expected to grow at a modest CAGR of 1.1% through 2032. While tissue valves remain clinically important, the market is mature and faces pressure from competing treatment options.

Growth is supported by improved durability, patient preference, and specialized valve designs. However, these positive factors are moderated by the shift toward transcatheter treatment and continued improvements in competing technologies.

As a result, suppliers must focus on product refinement, surgeon confidence, durability data, and global access to maintain stable performance in a slow-growth market.

Market Coverage and Data Scope

  • Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
  • Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
  • Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
  • Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
  • Device scope: The report covers tissue heart valves used in surgical heart valve replacement procedures, including stented, stentless, and sutureless tissue heart valves.

Markets Covered and Segmentation

Tissue Heart Valve Market

  • Device type: Stented, stentless, and sutureless heart valves.

Stented tissue heart valves are widely used surgical bioprosthetic valves supported by a frame. These products remain important because of their long clinical history, established surgeon familiarity, and broad availability across global markets.

Stentless tissue heart valves are designed without a supporting stent structure. This allows for a wider valve opening and can support more natural blood flow, particularly in patients requiring smaller valve sizes.

Sutureless tissue heart valves are designed to reduce implantation time and simplify surgical workflow. These products can help shorten operative times and may support adoption in cases where procedural efficiency is important.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how valve type, durability, surgical preference, patient selection, and competing transcatheter options are shaping the global tissue heart valve market.

Competitive Analysis

Edwards Lifesciences was the leader of the global tissue heart valve market in 2025. The company offers its Carpentier-Edwards(R) line of surgical heart valves, with aortic tissue valve products offered through the PERIMOUNT(R) portfolio.

Edwards Lifesciences benefits from a strong global presence, an established product line, and long-standing physician familiarity. These factors are expected to help the company maintain its market share over the forecast period.

Medtronic was the second-leading competitor in the global tissue heart valve market. Its product portfolio includes the Hancock(TM), Mosaic(TM), Avalus(TM), and additional surgical valve lines. The Hancock(TM) and Mosaic(TM) stented tissue heart valves are used for both aortic and mitral valve replacement.

Medtronic launched Avalus Ultra(TM), its next-generation surgical aortic tissue valve, in the U.S. in April 2024. This was followed by a commercial rollout in Western Europe in October 2024 and a launch in India in October 2025. This phased expansion shows Medtronic's strategy to broaden access to advanced tissue valve technologies.

Abbott was the third-leading competitor globally in 2025. Its tissue valve portfolio is centered on the Epic(TM) mitral and aortic stented tissue valves after the withdrawal of the Trifecta(TM) valve in 2023 due to early structural valve deterioration reports. This has weakened Abbott's position, especially in North America, and the company is not expected to gain significant share amid strong competition from Edwards Lifesciences, Medtronic, and Corcym.

Technology and Practice Trends

Sutureless Valve Adoption

Sutureless tissue valves are gaining attention because they can reduce operative time and simplify implantation. This is important in cardiac surgery, where shorter procedure times can support workflow efficiency and reduce time under anesthesia.

These devices are expected to remain an important area of product development.

Stentless Valve Performance

Stentless tissue valves can improve hemodynamic performance by allowing a wider valve opening and more natural blood flow.

This design is especially useful for patients who require smaller valve sizes, where stented designs may restrict flow.

Improved Tissue Processing

Advances in tissue processing are helping improve valve durability. Better durability makes tissue valves more attractive to patients and physicians, especially as the expected functional life of these products increases.

As durability improves, tissue valves may be considered for younger patient groups over time.

Reduced Need for Anticoagulation

Avoiding lifelong anticoagulation remains one of the strongest advantages of tissue valves. This benefit supports patient preference and helps distinguish tissue valves from mechanical options.

The ability to reduce long-term medication burden is especially important for older patients.

Surgical Valve Competition from TAVI

TAVI continues to reshape the valve replacement landscape. As transcatheter technologies expand into broader patient groups, traditional surgical tissue valves face competitive pressure.

This trend is especially important in aortic valve replacement.

Global Product Expansion

Leading companies are expanding tissue valve availability across major regions. Medtronic's Avalus Ultra(TM) launch sequence across the U.S., Western Europe, and India reflects a broader push to increase access to newer surgical valve technologies.

Global distribution and surgeon adoption will remain important competitive factors.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

  • How large is the global tissue heart valve market today, and how much is it expected to grow through 2032?
  • How are unit sales, procedure numbers, ASPs, and market values changing over time?
  • Which tissue valve types are shaping market demand?
  • How do stented, stentless, and sutureless tissue valves compare in adoption and growth?
  • Why do surgeons and patients often prefer tissue valves over mechanical valves?
  • How is improved durability expanding the potential patient population for tissue valves?
  • What role do stentless valves play in improving blood flow and long-term performance?
  • How is TAVI affecting demand for traditional surgical tissue valve replacement?
  • Which companies lead the global tissue heart valve market?
  • How are Edwards Lifesciences, Medtronic, and Abbott positioned in the competitive landscape?

The Global Tissue Heart Valve Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand surgical valve trends, and support commercial planning in the global tissue heart valve market.

TABLE OF CONTENT

Research Methodology

  • Step 1: Project Initiation & Team Selection
  • Step 2: Prepare Data Systems And Perform Secondary Research
  • Step 3: Preparation For Interviews & Questionnaire Design
  • Step 4: Performing Primary Research
  • Step 5: Research Analysis: Establishing Baseline Estimates
  • Step 6: Market Forecast And Analysis
  • Step 7: Identify Strategic Opportunities
  • Step 8: Final Review And Market Release
  • Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Tissue Heart Valve Market

  • 5.1 Executive Summary
    • 5.1.1 Global Tissue Heart Valve Market Overview
    • 5.1.2 Competitive Analysis
    • 5.1.3 Procedures Included
    • 5.1.4 Markets Included
    • 5.1.5 Regions Included
  • 5.2 Introduction
  • 5.3 Procedure Numbers
    • 5.3.1 Total Tissue Heart Valve Procedures
    • 5.3.2 Aortic Tissue Heart Valve Procedures
    • 5.3.3 Mitral Tissue Heart Valve Procedures
    • 5.3.4 Tricuspid Tissue Heart Valve Procedures
    • 5.3.5 Pulmonary Tissue Heart Valve Procedures
  • 5.4 Market Overview
    • 5.4.1 By Segment
    • 5.4.2 By Region
  • 5.5 Market Analysis And Forecast
    • 5.5.1 Total Tissue Heart Valve Market
    • 5.5.2 Stented Tissue Heart Valve Market
    • 5.5.3 Stentless Tissue Heart Valve Market
    • 5.5.4 Sutureless Tissue Heart Valve Market
  • 5.6 Drivers And Limiters
    • 5.6.1 Market Drivers
    • 5.6.2 Market Limiters
  • 5.7 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

  • Chart 5-1: Tissue Heart Valve Market, Global, 2022 & 2032
  • Chart 5-2: Tissue Heart Valve Procedures, Global, 2025
  • Chart 5-3: Tissue Heart Valve Procedures by Segment, Global, 2022 - 2032
  • Chart 5-4: Tissue Heart Valve Market by Segment, Global, 2022 - 2032
  • Chart 5-5: Tissue Heart Valve Market by Region, Global, 2022 - 2032
  • Chart 5-6: Leading Competitors, Tissue Heart Valve Market, Global, 2025

LIST OF FIGURES

  • Figure 5-1: Tissue Heart Valve Procedures Covered
  • Figure 5-2: Tissue Heart Valve Markets Covered
  • Figure 5-3: Tissue Heart Valve Regions Covered, Global (1 of 2)
  • Figure 5-4: Tissue Heart Valve Regions Covered, Global (2 of 2)
  • Figure 5-5: Tissue Heart Valve Procedures by Segment, Global, 2022 - 2032
  • Figure 5-6: Tissue Heart Valve Procedures by Region, Global, 2022 - 2032
  • Figure 5-7: Tissue Heart Valve Procedures by Country, North America, 2022 - 2032
  • Figure 5-8: Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 5-9: Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 5-10: Tissue Heart Valve Procedures by Country, Western Europe, 2022 - 2032
  • Figure 5-11: Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 5-12: Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 5-13: Tissue Heart Valve Procedures by Country, Middle East, 2022 - 2032
  • Figure 5-14: Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 5-15: Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 5-16: Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 5-17: Tissue Heart Valve Procedures by Country, Africa, 2022 - 2032
  • Figure 5-18: Aortic Tissue Heart Valve Procedures by Region, Global, 2022 - 2032
  • Figure 5-19: Aortic Tissue Heart Valve Procedures by Country, North America, 2022 - 2032
  • Figure 5-20: Aortic Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 5-21: Aortic Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 5-22: Aortic Tissue Heart Valve Procedures by Country, Western Europe, 2022 - 2032
  • Figure 5-23: Aortic Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 5-24: Aortic Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 5-25: Aortic Tissue Heart Valve Procedures by Country, Middle East, 2022 - 2032
  • Figure 5-26: Aortic Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 5-27: Aortic Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 5-28: Aortic Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 5-29: Aortic Tissue Heart Valve Procedures by Country, Africa, 2022 - 2032
  • Figure 5-30: Mitral Tissue Heart Valve Procedures by Region, Global, 2022 - 2032
  • Figure 5-31: Mitral Tissue Heart Valve Procedures by Country, North America, 2022 - 2032
  • Figure 5-32: Mitral Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 5-33: Mitral Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 5-34: Mitral Tissue Heart Valve Procedures by Country, Western Europe, 2022 - 2032
  • Figure 5-35: Mitral Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 5-36: Mitral Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 5-37: Mitral Tissue Heart Valve Procedures by Country, Middle East, 2022 - 2032
  • Figure 5-38: Mitral Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 5-39: Mitral Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 5-40: Mitral Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 5-41: Mitral Tissue Heart Valve Procedures by Country, Africa, 2022 - 2032
  • Figure 5-42: Tricuspid Tissue Heart Valve Procedures by Region, Global, 2022 - 2032
  • Figure 5-43: Tricuspid Tissue Heart Valve Procedures by Country, North America, 2022 - 2032
  • Figure 5-44: Tricuspid Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 5-45: Tricuspid Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 5-46: Tricuspid Tissue Heart Valve Procedures by Country, Western Europe, 2022 - 2032
  • Figure 5-47: Tricuspid Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 5-48: Tricuspid Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 5-49: Tricuspid Tissue Heart Valve Procedures by Country, Middle East, 2022 - 2032
  • Figure 5-50: Tricuspid Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 5-51: Tricuspid Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 5-52: Tricuspid Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 5-53: Tricuspid Tissue Heart Valve Procedures by Country, Africa, 2022 - 2032
  • Figure 5-54: Pulmonary Tissue Heart Valve Procedures by Region, Global, 2022 - 2032
  • Figure 5-55: Pulmonary Tissue Heart Valve Procedures by Country, North America, 2022 - 2032
  • Figure 5-56: Pulmonary Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 5-57: Pulmonary Tissue Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 5-58: Pulmonary Tissue Heart Valve Procedures by Country, Western Europe, 2022 - 2032
  • Figure 5-59: Pulmonary Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 5-60: Pulmonary Tissue Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 5-61: Pulmonary Tissue Heart Valve Procedures by Country, Middle East, 2022 - 2032
  • Figure 5-62: Pulmonary Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 5-63: Pulmonary Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 5-64: Pulmonary Tissue Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 5-65: Pulmonary Tissue Heart Valve Procedures by Country, Africa, 2022 - 2032
  • Figure 5-66: Tissue Heart Valve Market by Segment, Global, 2022 - 2032 (US$M)
  • Figure 5-67: Tissue Heart Valve Market by Region, Global, 2022 - 2032 (US$M)
  • Figure 5-68: Tissue Heart Valve Market, Global, 2022 - 2032
  • Figure 5-69: Units Sold by Region, Tissue Heart Valve Market, Global, 2022 - 2032
  • Figure 5-70: Average Selling Price by Region, Tissue Heart Valve Market, Global, 2022 - 2032 (US$)
  • Figure 5-71: Market Value by Region, Tissue Heart Valve Market, Global, 2022 - 2032 (US$M)
  • Figure 5-72: Stented Tissue Heart Valve Market, Global, 2022 - 2032
  • Figure 5-73: Units Sold by Region, Stented Tissue Heart Valve Market, Global, 2022 - 2032
  • Figure 5-74: Average Selling Price by Region, Stented Tissue Heart Valve Market, Global, 2022 - 2032 (US$)
  • Figure 5-75: Market Value by Region, Stented Tissue Heart Valve Market, Global, 2022 - 2032 (US$M)
  • Figure 5-76: Stentless Tissue Heart Valve Market, Global, 2022 - 2032
  • Figure 5-77: Units Sold by Region, Stentless Tissue Heart Valve Market, Global, 2022 - 2032
  • Figure 5-78: Average Selling Price by Region, Stentless Tissue Heart Valve Market, Global, 2022 - 2032 (US$)
  • Figure 5-79: Market Value by Region, Stentless Tissue Heart Valve Market, Global, 2022 - 2032 (US$M)
  • Figure 5-80: Sutureless Tissue Heart Valve Market, Global, 2022 - 2032
  • Figure 5-81: Units Sold by Region, Sutureless Tissue Heart Valve Market, Global, 2022 - 2032
  • Figure 5-82: Average Selling Price by Region, Sutureless Tissue Heart Valve Market, Global, 2022 - 2032 (US$)
  • Figure 5-83: Market Value by Region, Sutureless Tissue Heart Valve Market, Global, 2022 - 2032 (US$M)
  • Figure 5-84: Leading Competitors, Tissue Heart Valve Market, Global, 2025